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Abstract
To date, the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC)
tumor, nodes, metastasis (TNM) classification represents the standard system for evaluation of prognosis in solid
tumors. However, the clinical outcome can be significantly different in patients with the same TNM stage.
Therefore, many efforts have been made aiming to define new prognostic parameters.
Indeed, analyses conducted in large cohorts of colorectal cancer patients emphasized the prognostic value of tumor-
infiltrating lymphocytes, leading to the development of a prognostic score referred to as “Immunoscore”.
In this commentary, we recapitulate the study by Gabrielson and colleagues, recently published in Cancer Immunology
Research, addressing the role of intratumoral CD3+ and CD8+ T cells as well as as prognostic markers for hepatocellular
carcinoma.
The authors demonstrate that Immunoscore represents a valuable prognostic marker in patients with hepatocellular
carcinoma who have undergone primary tumor resection, supporting its application in a tumor setting other than
colorectal cancer.
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Background
Hepatocellular carcinoma (HCC) is the most common
primary liver malignancy and accounts for about 6 % of
all new cancers diagnosed worldwide. It is the third and
the fifth leading cause of death from cancer in men and
women, respectively. More than 50 % of HCC cases can
be attributed to HBV chronic infection, whereas HCV
chronic infection accounts for 30 % of cases. Approxi-
mately 15 % of HCC cases can be associated with non-
viral causes, including alcohol, aflatoxins, metabolic liver
diseases, steatosis, non-alcoholic fatty liver disease. The
overall prognosis for HCC patients is poor, with a 5-year
survival rate of 5–6 % [1, 2].
Several strategies are employed in the management
of HCC according to the extent of liver disease. In
particular, in early-stage HCC, surgery (i.e., tumor
resection and liver transplantation) represents the
standard method. However, radiofrequency (RF), ther-
mal ablation and trans-arterial chemoembolization
(TACE) provide a second line therapy for patients
with unresectable HCC or for those who are not
eligible for liver transplantation [3].
In this perspective, evaluation of prognosis represents
a crucial step for proper management of HCC patients.
Accordingly, HCC prognosis is closely related to its
stage. To date, several staging systems are employed to
estimate life expectancy of HCC patients, none of which
has been universally adopted. In particular, four features
have been recognized as being important determinants
of survival: the severity of underlying liver disease, the
size of the tumor, extension of the tumor into adjacent
structures, and the presence of metastases [4, 5]. The
TNM classification system, uses T (i.e., tumor size and
number), N (i.e., regional lymph node involvement) and
M (i.e., metastasis) parameters to stage the disease and
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stratify patients according to the tumor characteristics
(Table 1) [6].
However, the clinical outcome (i.e., relapse-free survival
(RFS) and overall survival (OS)) can be significantly differ-
ent in HCC patients within the same TNM stage of dis-
ease. Therefore, many efforts have been made to define
new parameters with more precise prognostic value and
the search for HCC prognostic markers, in a setting of ex-
treme heterogeneity, is gaining momentum. Several bio-
markers have been described, so far, for both biological
characterization of the tumor and evaluation of prognosis.
In particular, the prognostic significance of the estro-
gen receptor (ER) in patients with HCC was investigated
in a study showing that patients with wild-type ER may
experience better survival than those presenting a vari-
ant ER [7]. However, ER characterization requires quite
invasive procedure (i.e., liver biopsy). In this perspective,
more recently, several studies have been focused on the
identification of new serological markers for routine
analysis application (reviewed in [8, 9]).
Serum Dickkopf-1 (DKK1) has been suggested as a po-
tential prognostic marker for HCC in combination with
alpha-fetoprotein (AFP) [10]. Similarly, a recent study
showed that plasma osteopontin (OPN) combined with
serum AFP can be used as prognostic marker in patients
with early-stage HCC [11]. In addition, low serum
levels of vascular endothelial growth factor (VEGF)
seem to be associated with longer survival [12].
Moreover, plasma levels of insulin-like growth factor-
1 (IGF-1) correlate with time-to-recurrence, as well as
OS [13]. Although these new serological markers have
shown promising results, they still require further
evaluation and clinical validation.
Interestingly, the HCC microenvironment comprises
a network of cells that play a critical role in tumor
progression influencing prognosis. Several studies have
shown a correlation between HCC prognosis and
tumor-infiltrating cells affecting tumor growth, inva-
sion, angiogenesis and metastasis, including: tumor as-
sociated macrophages (TAMs), hepatic stellate cells
(HSCs), cancer-associated fibroblasts (CAFs), neutro-
phils, cancer stem-like cells (CSLCs) and Tregs. Unfor-
tunately, none of these cells is validated yet for routine
prognostic assessment [14].
In this scenario, the pioneering study of Galon’s group
conducted on a large cohort of colorectal cancer (CRC)
patients which led to the assessment of the tumor-
infiltrating immune cells as valuable prognostic marker
for the treatment of CRC [15]. The type, density and
location of immune cells within distinct tumor regions,
including tumor interior (TI) and invasive margin (IM),
referred to as “Immunoscore”, was recognized as better
predictor of clinical outcome than the standard TNM
stage classification [16, 17].
Tumor-infiltrating lymphocytes (TILs) as prognostic factor
for HCC
In line with such evidence, the study by Gabrielson et al.
recently published in Cancer Immunology Research rep-
resents one of the first papers addressing the cumulative
role of intratumoral CD3+ and CD8+ T cells, as well as
programmed death ligand 1 (PD-L1) as prognostic
markers for hepatocellular carcinoma [18].
The authors reviewed survival data of 65 HCC patients
(stage I to IV), who underwent primary tumor resection
between 2006 and 2015. The mean follow-up was
39.7 months. Surgical tissue specimens were analyzed.
Immunohistochemistry (IHC) staining with monoclonal
antibodies to CD3, CD8 and PD-L1 was performed for
biomarker imaging in TI, IM and noncancerous liver
parenchyma. The median immune cell density was used
to stratify patients into groups according to the Immu-
noscore as defined by Galon et al. in CRC [17].
Patients with low densities of CD3+ and CD8+ T cells
in both TI and IM tumor regions were classified as Im0;
patients with one high density for one marker were clas-
sified as Im1; patients with two, three and four high
densities for the two markers were classified as Im2,
Im3, and Im4, respectively.
The authors observed a statistically significant associ-
ation between intratumoral CD3+ and CD8+ T cells and
frequency of HCC recurrence. In particular, patients
with a high density of CD3+ immune infiltrates in the TI
and IM regions experienced recurrence of HCC only in
15 % of cases compared with 44 % in those with a low
CD3+ cell density (P = 0.027). Similarly, patients with a
high density of CD8+ immune infiltrates experienced re-
currence of HCC in 15 % of cases compared with 45 %
of those with a low CD8+ T cell density (P = 0.014). The
Table 1 TNM classification for staging of hepatocellular carcinoma
Stage T N M
I T1 N0 M0
II T2 N0 M0
IIIa T3a N0 M0
IIIb T3b N0 M0
IIIc T4 N0 M0
IVa Any T N1 M0
IVb Any T Any N M1
T1: single tumor without vascular invasion
T2: single tumor with vascular invasion or multiple tumors, none > 5 cm
T3a: multiple tumors > 5 cm
T3b: tumor involving a major branch of the portal or hepatic vein
T4: tumor with direct invasion of adjacent organs other than gallbladder or
with perforation of visceral peritoneum
N0: no regional lymph node metastasis
N1: regionallymph node metastasis
M0: no distant metastasis
M1: distant metastasis
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frequency of HCC recurrence in each Immunoscore sub-
group was 65 % for Im0, 22 % for Im1, 10 % for Im2,
10 % for Im3, and 11 % for Im4. In addition, high dens-
ities of CD3+ and CD8+ T cells in both TI and IM re-
gions, along with corresponding Immunoscores, were
significantly associated with a prolonged RFS (P = 0.002).
Interestingly, the present study confirms the data of a
previous study by Sun and colleagues who showed that
distribution and densities of CD3+ and CD8+ T cells in
central tumor regions represent a predictive tool for
HCC progression [19].
The authors also tested PD-L1 expression in relation
to CD3+ and CD8+ T cells density. Indeed, expression of
PD-L1 correlated with high density of CD3+ and CD8+
T cells (P = 0.024 and 0.005, respectively). PD-L1 expres-
sion predicted lower recurrence rate (P = 0.034), as well
as prolonged RFS (P = 0.029) [18].
Taken together, these data underline the relevance of
Immunoscore and PD-L1 expression as prognostic
markers in patients who have undergone HCC resection.
Perspectives
The study by Gabrielson et al. clearly pointed out a posi-
tive correlation between PD-L1 expression and CD3+
and CD8+ T cells densities. Interestingly, 19 samples
showed PD-L1 expression in non-malignant cells around
the tumor area. The authors argued that PD-L1 inhibi-
tory pathway represents a negative feedback mechanism
that follows, rather than precedes, CD8+ T cell infiltra-
tion [18]. The authors also described mechanistic studies
showing that upregulated expression of PD-L1 in mice is
driven by IFNγ and depends on the presence of CD8+ T
cells in the tumor microenvironment.
Several studies have been focused on analysis of the
prognostic significance of PD-L1 expression with very
contrasting results [20–22].
However, a recent study reported that tumor expres-
sion of PD-L1 in melanoma is associated with the pres-
ence of TILs and a strong expression of IFNγ [23].
In another study on melanoma and non-small cell
lung carcinoma (NSCLC), PD-L1 tumor expression was
associated with the presence of immune infiltration. In
this study, expression of PD-L1 was associated with
good clinical response [24].
In addition, a recent study reported that HPV-positive
head and neck squamous cell carcinoma (HNSCC) is
more likely associated with intratumoral T cell infiltration,
as well as PD-L1 expression, with favorable outcome [25].
Indeed, a tumor microenvironment characterized by
PD-L1 expressing cells in a context of immune infiltra-
tion could be a favorable ground for immunotherapy ap-
proaches targeting regulatory immune checkpoints, such
as PD-L1. Preexisting natural cytotoxic T cells at the
tumor site seem to be necessary to induce anti-tumor
immune response with anti PD-L1. Indeed, anti PD-L1
immunotherapy has been shown to benefit patients with
preexisting T cell infiltration.
In line with such evidence, anti-PD-L1 agents have dem-
onstrated strong clinical activity in a wide variety of tumors
and are currently tested in several tumor settings [26].
In particular, a combination therapy based on Durva-
lumab (monoclonal antibody against PD-L1) and Treme-
limumab (monoclonal antibody against CTLA-4) is
currently evaluated in patients with advanced HCC
(ClinicalTrials.gov Identifier: NCT02821754).
Overall, the study performed by Gabrielson and col-
leagues not only supports the application of the Immu-
noscore as prognostic marker for HCC, but also sheds
light on a complex and contrasting topic that is the
rationale for using PD-L1 expression as marker of prog-
nostic significance in HCC.
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